<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:NCBITaxon="http://purl.obolibrary.org/obo/NCBITaxon#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:ncbitaxon="http://purl.obolibrary.org/obo/ncbitaxon#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>J Antimicrob Chemother <br /> doi:10.1093/jac/dkq103 <br />  <br />  <br />  <br />  <br />     PhoY2 PhoY1 PhoU homologue involved persisters <br />                      <span id='am-1' about='obo:NCBITaxon_1763' typeof='obo:NCBITaxon_85007 owl:Thing obo:NCBITaxon_1762 obo:NCBITaxon_1 obo:NCBITaxon_1760 obo:NCBITaxon_131567 obo:NCBITaxon_2 obo:NCBITaxon_2037 obo:NCBITaxon_201174 obo:NCBITaxon_85003'><span id='am-2' property="oboInOwl:hasDbXref" content="PMID:16014496" datatype="xsd:string"></span><span id='am-3' property="oboInOwl:hasDbXref" content="PMID:1581193" datatype="xsd:string"></span><span id='am-4'  ></span><span id='am-5' property="oboInOwl:hasDbXref" content="PMID:1883713" datatype="xsd:string"></span><span id='am-6' property="oboInOwl:hasDbXref" content="PMID:7547284" datatype="xsd:string"></span><span id='am-7' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-8' property="oboInOwl:hasDbXref" content="PMID:7907223" datatype="xsd:string"></span><span id='am-9' property="oboInOwl:hasDbXref" content="PMID:7547304" datatype="xsd:string"></span><span id='am-10' property="oboInOwl:hasDbXref" content="PMID:1380284" datatype="xsd:string"></span><span id='am-11' property="oboInOwl:hasDbXref" content="PMID:8863452" datatype="xsd:string"></span><span id='am-12' property="oboInOwl:hasRelatedSynonym" content="Mycobacterium Lehmann and Neumann 1896" datatype="xsd:string"></span><span id='am-13' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-14' property="rdfs:label" content="Mycobacterium" datatype="xsd:string"></span><span id='am-15' property="oboInOwl:hasDbXref" content="PMID:2275850" datatype="xsd:string"></span>Mycobacterium</span> tuberculosis <br />                                                    Wanliang Shi Ying Zhang * <br />  <br />        Department Molecular Microbiology Immunology, Bloomberg School Public Health, Johns Hopkins University, <br />                                                   Baltimore, MD 21205, USA <br />  <br />                        *Corresponding author. Tel: +1-410-614-2975; Fax: +1-410-955-0105; E-mail: yzhang@jhsph.edu <br />  <br />              Received 10 November 2009; returned 22 January 2010; revised 18 February 2010; accepted 5 March 2010 <br />  <br />            Objectives: Mycobacterial persistence thought underlying cause current lengthy tuberculosis <br />            therapy latent infection. Despite recent progress, mechanisms bacterial persistence poorly <br />            understood. We recently identified new persister gene phoU <span id='am-98' about='obo:NCBITaxon_562' typeof='owl:Thing obo:NCBITaxon_561 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_91347 obo:NCBITaxon_1224 obo:NCBITaxon_2 obo:NCBITaxon_543 obo:NCBITaxon_1236'><span id='am-99' property="oboInOwl:hasRelatedSynonym" content="Eschericia coli" datatype="xsd:string"></span><span id='am-100' property="oboInOwl:hasAlternativeId" content="NCBITaxon:662104" datatype="xsd:string"></span><span id='am-101' property="oboInOwl:hasDbXref" content="PMID:10319482" datatype="xsd:string"></span><span id='am-102' property="oboInOwl:hasRelatedSynonym" content="Escherchia coli" datatype="xsd:string"></span><span id='am-103' property="oboInOwl:hasAlternativeId" content="NCBITaxon:662101" datatype="xsd:string"></span><span id='am-104' property="oboInOwl:hasRelatedSynonym" content="bacterium E3" datatype="xsd:string"></span><span id='am-105' property="oboInOwl:hasRelatedSynonym" content="Bacillus coli" datatype="xsd:string"></span><span id='am-106'  ></span><span id='am-107' property="oboInOwl:hasRelatedSynonym" content="Enterococcus coli" datatype="xsd:string"></span><span id='am-108' property="oboInOwl:hasExactSynonym" content="Escherichia/Shigella coli" datatype="xsd:string"></span><span id='am-109' property="oboInOwl:hasRelatedSynonym" content="Bacterium coli commune" datatype="xsd:string"></span><span id='am-110' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-111' property="rdfs:label" content="Escherichia coli" datatype="xsd:string"></span><span id='am-112' property="oboInOwl:hasRelatedSynonym" content="Bacterium coli" datatype="xsd:string"></span><span id='am-113' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span>Escherichia coli</span> shown that <br />            phoU mutant defect persisters. The objective study evaluate role phoU <br />            homologues phoY1 phoY2 <span id='am-16' about='obo:NCBITaxon_1773' typeof='obo:NCBITaxon_85007 owl:Thing obo:NCBITaxon_1762 obo:NCBITaxon_1763 obo:NCBITaxon_1 obo:NCBITaxon_1760 obo:NCBITaxon_131567 obo:NCBITaxon_2 obo:NCBITaxon_2037 obo:NCBITaxon_201174 obo:NCBITaxon_85003 obo:NCBITaxon_77643'><span id='am-17' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-18'  ></span><span id='am-19' property="oboInOwl:hasRelatedSynonym" content="Bacillus tuberculosis" datatype="xsd:string"></span><span id='am-20' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-21' property="oboInOwl:hasRelatedSynonym" content="Mycobacterium tuberculosis var. hominis" datatype="xsd:string"></span><span id='am-22' property="rdfs:label" content="Mycobacterium tuberculosis" datatype="xsd:string"></span><span id='am-23' property="oboInOwl:hasRelatedSynonym" content="Mycobacterium tuberculosis typus humanus" datatype="xsd:string"></span><span id='am-24' property="oboInOwl:hasRelatedSynonym" content="Bacterium tuberculosis" datatype="xsd:string"></span>Mycobacterium tuberculosis</span> mycobacterial persistence. <br />            Methods: M. tuberculosis phoY1 phoY2 mutant strains constructed. The persister-related phenotypes <br />            phoY1 phoY2 mutants assessed vitro MIC testing, drug exposure assays by <br />            survival mouse model tuberculosis infection. <br />            Results: We demonstrated M. tuberculosis PhoY2 equivalent E. coli PhoU inactivation of <br />            phoY2 phoY1 caused defect persistence phenotype shown increased susceptibility rifam- <br />            picin pyrazinamide MIC testing drug exposure assays reduced persistence the <br />            mouse model. <br />            Conclusions: <span id='am-35' about='obo:NCBITaxon_169495' typeof='owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_169440 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_7147 obo:NCBITaxon_43733 obo:NCBITaxon_33154 obo:NCBITaxon_43738 obo:NCBITaxon_480117 obo:NCBITaxon_33317 obo:NCBITaxon_169449 obo:NCBITaxon_480118 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_43750 obo:NCBITaxon_33208 obo:NCBITaxon_85512 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_7203 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_33392 obo:NCBITaxon_169455 obo:NCBITaxon_50557 obo:NCBITaxon_43741'><span id='am-36' property="rdfs:label" content="This" datatype="xsd:string"></span><span id='am-37' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-38'  ></span><span id='am-39' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>This</span> study provides validation PhoU involved persistence E. coli but <br />            M. tuberculosis implications development new drugs targeting persisters improved <br />            treatment. <br />  <br /> Keywords: mycobacterial persistence, mutants, antibiotics <br />  <br />  <br />  <br />  <br /> Introduction                                                            developing new drugs target persisters shorten <br />                                                                         TB therapy.6,7 <br /> Tuberculosis (TB) leading infectious killer worldwide                   Persisters described Hobby et al. 8 1942 when <br /> despite chemotherapy BCG vaccine. The causative agent               penicillin killed 99% streptococcal culture <br /> Mycobacterium tuberculosis highly successful pathogen,             leaving 1% bacterial population intact. This phenomenon <br /> which latently infected one-third world population           carefully defined Bigger 1944 coined the <br /> and causes 9 million new TB cases 1.6 million deaths                term &#8216;persisters&#8217; 1% surviving bacteria killed peni- <br /> worldwide year.1 This global TB situation expected           cillin.9 Although persisters initially defined using log phase <br /> be exacerbated spread HIV infection increasing            cultures contain small number non-growing persisters, <br /> emergence multidrug-resistant TB (MDR-TB) exten-                 <span id='am-121' about='obo:IAO_0000115' typeof='owl:Thing'>definition</span> persisters subsequently extended to <br /> sively drug-resistant TB (XDR-TB).2 &#8211; 4 Although current TB         include non-growing persisters enriched station- <br /> therapy cure disease, long takes               ary phase cultures.10,11 Thus, antibiotic-tolerant bacteria are <br /> least 6 months. The lengthy TB therapy makes patient compli-            killed antibiotics regrow absence anti- <br /> ance difficult frequently causes selection drug-resistant        biotics remain susceptible antibiotics are <br /> strains. The lengthy TB therapy thought to             called persisters. Persisters characterized slow no <br /> presence mycobacterial persisters effectively           growth low metabolic activity phenotypic resistance <br /> killed current TB drugs.5,6 Due problem                antibiotics.10 The presence persister phenomenon has <br /> drug-resistant persister TB, currently great             documented numerous bacterial <span id='am-40' about='obo:NCBITaxon_species' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-41' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-42' property="rdfs:label" content="species" datatype="xsd:string"></span>species</span> including <br /> deal understanding persister mechanisms              M. tuberculosis.5,6,11 Persisters biofilms bacterial <br />  <br /> # The Author 2010. Published Oxford University Press behalf British Society Antimicrobial Chemotherapy. All rights reserved. <br /> For Permissions, e-mail: journals.permissions@oxfordjournals.org <br />  <br />                                                                                                                                        1237 <br />  Shi Zhang <br />  <br />  <br />  <br /> infections pose significant challenge treatment disease         phenotype complemented functional <br /> control.5,11 Despite original observation persistence          wild-type phoY2 gene. <br /> phenomenon 60 years ago, mechanisms persister for- <br /> mation poorly understood. Recent studies suggest that <br /> toxin &#8211; antitoxin (TA) modules involved persister for- <br />                                                                           Materials methods <br /> mation.11 The TA module linked persistence <span id='am-114' about='obo:NCBITaxon_561' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_91347 obo:NCBITaxon_1224 obo:NCBITaxon_2 obo:NCBITaxon_543 obo:NCBITaxon_1236'><span id='am-115' property="oboInOwl:hasRelatedSynonym" content="Escherchia" datatype="xsd:string"></span><span id='am-116' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-117' property="rdfs:label" content="Escherichia" datatype="xsd:string"></span><span id='am-118'  ></span><span id='am-119' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-120' property="oboInOwl:hasDbXref" content="PMID:19700542" datatype="xsd:string"></span>Escherichia</span>        Bacterial growth conditions <br /> coli HipBA.12 HipB HipA, like TA modules as <br />                                                                           Bacterial strains <span id='am-133' about='obo:NCBITaxon_36549' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_28384'><span id='am-134' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-135' property="rdfs:label" content="plasmids" datatype="xsd:string"></span><span id='am-136' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-137' property="oboInOwl:hasAlternativeId" content="NCBITaxon:2435" datatype="xsd:string"></span>plasmids</span> used shown Table 1. E. coli strains <br /> RelBE MazEF, organized operon gene <br />                                                                           grown <span id='am-25' about='obo:NCBITaxon_218032' typeof='owl:Thing obo:NCBITaxon_33208 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_33154 obo:NCBITaxon_1206795 obo:NCBITaxon_216294 obo:NCBITaxon_69557 obo:NCBITaxon_69555 obo:NCBITaxon_69556 obo:NCBITaxon_6447 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6448 obo:NCBITaxon_216293 obo:NCBITaxon_6072'><span id='am-26' property="rdfs:label" content="Luria" datatype="xsd:string"></span><span id='am-27'  ></span><span id='am-28' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-29' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Luria</span>&#8211;Bertani (LB) broth LB broth agar. Mycobacter- <br /> hipB encoding antitoxin, located upstream toxin                ium smegmatis mc2155 grown LB broth containing 0.5% glycerol, <br /> gene hipA.13 Overexpression wild-type toxin HipA            0.5% dextrose 0.05% Tween 80. M. tuberculosis strain H37Rv was <br /> RelE caused 10- 1000-fold persisters.14,15 HipA               grown 7H9 liquid medium (Difco) supplemented 0.05% Tween <br /> RelE inhibit macromolecule (protein, RNA DNA) syn-              80 10% bovine serum albumin&#8211; dextrose&#8211; catalase (ADC) enrich- <br /> thesis slow stop cell division, raising possi-       ment (Difco) 378C  2&#8211; 3 weeks occasional agitation. When <br /> bility toxins TA modules involved persister         required, following antibiotics used specified concen- <br /> formation.11 However, deletion TA modules hipA did             trations: kanamycin (25 mg/L) hygromycin B (150 mg/L E. coli <br /> not cause defect persistence15,16 presumably            50 mg/L M. tuberculosis). <br /> redundancy genome. A recent study showed overex- <br /> pression unrelated toxic proteins, heat shock protein          Knockout mutant construction complementation <br /> DnaJ protein PmrC, caused higher persister formation.17 <br /> This finding questions significance TA modules specific       phoY1 phoY2 genes M. tuberculosis H37Rv disrupted using <br /> and universal mechanism persister formation.                          specialized transduction described previously.20 To create phoY1::hyg <br />                                                                           phoY2::hyg, hygromycin resistance cassette used to <br />     In M. tuberculosis, isocitrate lyase (ICL), required fatty acid <br />                                                                           replace respective gene&#8217;s open reading frames. Successful deletion <br /> catabolism, involved mycobacterial persist-            gene confirmed junction PCR DNA sequencing. For <br /> ence.18 In addition, inactivation RelA led defect persist-     complementation deletion mutants, wild-type phoY1 phoY2 <br /> ence mouse model.19 We recently identified new              genes amplified H37Rv genomic DNA PCR cloned <br /> persister gene phoU, involved persister formation E. coli.16        mycobacterial shuttle vector pMV261 followed electroporation <br /> PhoU negative regulator pst operon involved <span id='am-138' about='obo:NCBITaxon_128483' typeof='owl:Thing obo:NCBITaxon_33208 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_33154 obo:NCBITaxon_216303 obo:NCBITaxon_37796 obo:NCBITaxon_1206795 obo:NCBITaxon_69555 obo:NCBITaxon_6447 obo:NCBITaxon_33317 obo:NCBITaxon_6448 obo:NCBITaxon_2759 obo:NCBITaxon_6479 obo:NCBITaxon_216293 obo:NCBITaxon_6072'><span id='am-139' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-140'  ></span><span id='am-141' property="rdfs:label" content="Phos" datatype="xsd:string"></span><span id='am-142' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>phos</span>-          mutants described previously.21 Primers used construct <br /> phate uptake function known. We recently showed            phoY1 phoY2 mutants complementation shown Table 1. <br /> that inactivation phoU E. coli leads dramatic defect in <br /> persister phenotype demonstrated reduced persister <br /> numbers persister assays increased susceptibility a <br />                                                                           MIC/MBC determination drug exposure assays <br /> diverse range antibiotics stress conditions (acid pH, star-        The MICs isoniazid rifampicin determined using serial <br /> vation, etc.), especially stationary phase starved cultures         2-fold dilutions compound 7H9 medium 7H11 agar. <br /> compared log phase cultures.16 Microarray studies indicated          The MIC pyrazinamide determined 7H9 medium 7H11 <br /> that E. coli phoU mutant surprisingly expressed high levels        agar pH 5.6. The initial cell density 105 cfu/mL log phase <br />                                                                           culture, samples incubated 15 days 378C. The MIC <br /> genes involved energy production metabolism, efflux/ <br />                                                                           recorded minimum drug concentration prevented <br /> transport, flagella chemotaxis synthesis, suggesting <br />                                                                           visible growth, MBC recorded drug concentration <br /> that PhoU global repressor cellular metabolism           reduced cfu 100-fold seeded inoculum MIC <br /> inactivation leads hyperactive metabolic state under-         testing. <br /> lying cause persistence defect. This study provides          For drug exposure persister assays, survival stationary phase <br /> evidence PhoU master regulator, role             cultures phoY1 phoY2 mutants wild-type H37Rv to <br /> phosphate metabolism, involved persister formation.              pyrazinamide (200 mg/L) rifampicin (8 mg/L) determined. <br /> We proposed model based PhoU serves                   Drug exposure pyrazinamide performed acidic medium <br /> general repressor cellular metabolism suppress cellular             pH 5.5 described previously.22 The drug exposure carried out <br /> metabolic activity facilitate persister formation.16 PhoU         period 3 &#8211;9 days 378C shaking. Aliquots bacterial <br /> ubiquitous protein present virtually bacterial species, includ-    cultures exposed drug taken different timepoints and <br /> ing M. tuberculosis.16                                                    washed PBS buffer plating 7H11 agar plates cfu count. <br />     M. tuberculosis, notorious ability persist <br /> in vivo despite antibiotic treatment, PhoU homologues,            Survival persistence DphoY1 DphoY2 mutants <br /> PhoY1 PhoY2,16 share 63.4% amino acid identity               mouse model <br /> each other. PhoY1 PhoY2 have, respectively, 40% 44% <br /> homology E. coli PhoU. The role PhoY1 PhoY2 per-         Six-week-old female BALB/c mice (NCI, Frederick, MD, USA) infected <br />                                                                           tail vein M. tuberculosis strain H37Rv, DphoY1 mutant, <br /> sistence M. tuberculosis unclear. In study, con- <br />                                                                           DphoY2 mutant respective mutant complemented strains (all <br /> structed mutants PhoU homologues phoY1 phoY2 and <br />                                                                            1&#215;104 cfu) 100 mL PBS/0.05% Tween 80 using low dose <br /> evaluated role PhoY1 PhoY2 persistence               latent infection model described previously.23 Mice (five mice per <br /> M. tuberculosis. We M. tuberculosis phoY2 equiv-         group) infected different mycobacterial strains were <br /> alent E. coli phoU inactivation phoY2 phoY1        housed BSL-3 animal facility. After 8 weeks infection, mice were <br /> caused defect persistence phenotype including increased          sacrificed infected organs (lungs spleens) homogen- <br /> susceptibility antibiotics decreased persister formation        ized PBS/0.05% Tween 80, homogenates appropriate <br /> vitro, reduced persistence mouse model,                 dilutions plated 7H11 plates containing 10% ADC the <br />  <br />  <br />  <br /> 1238 <br />  PhoU homologue PhoY2 involved TB persistence                                                                                      JAC <br /> Table 1. Bacterial strains, plasmids, phage primers used study <br />  <br />                                                                    Description                                              Source reference <br />  <br /> Strains <br />   E. coli HB101              F2 hsdS20 (rB2 mB) supE44 <span id='am-30' about='obo:NCBITaxon_9225' typeof='owl:Thing obo:NCBITaxon_33213 obo:NCBITaxon_1329799 obo:NCBITaxon_1 obo:NCBITaxon_32523 obo:NCBITaxon_131567 obo:NCBITaxon_32524 obo:NCBITaxon_436489 obo:NCBITaxon_117570 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_9224 obo:NCBITaxon_117571 obo:NCBITaxon_9223 obo:NCBITaxon_33154 obo:NCBITaxon_8782 obo:NCBITaxon_436486 obo:NCBITaxon_1338369 obo:NCBITaxon_8287 obo:NCBITaxon_2759 obo:NCBITaxon_8492 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_8825 obo:NCBITaxon_7776 obo:NCBITaxon_436492 obo:NCBITaxon_32561 obo:NCBITaxon_8457 obo:NCBITaxon_436491'><span id='am-31' property="rdfs:label" content="Ara" datatype="xsd:string"></span><span id='am-32' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-33' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-34'  ></span>ara</span>-14 galK-2 lacY1 proA2 rpsL20 (Smr) xyl-5 mtl-1&#8211;recA13      ATCC <br />   M. smegmatis mc2155        high-frequency transformation mutant M. smegmatis ATCC 607                            W. R. Jacobs Jr <br />   M. tuberculosis H37Rv      wild-type strain                                                                         ATCC <br />  <br /> Plasmids <br />   p0004s                     hygromycin resistance plasmid                                                            W. R. Jacobs Jr <br />   pMV261                     E. coli&#8211;Mycobacteria shuttle vector                                                      C. K. Stover <br />  <br /> Phage <br />   phAE159                    temperature-sensitive phage mycobacteria                                             W. R. Jacobs Jr <br />  <br /> Primers <br />    Y1KLL                     5&#8242; -TTTTTTTTCCATAAATTGGGAAAGCGACGACACCTCCAAGC-3&#8242;                                           phoY1 knockout <br />    Y1KLR                     5&#8242; -TTTTTTTTCCATTTCTTGGAACGCTTCCTTTTCGACTTGGG-3&#8242;                                           phoY1 knockout <br />    Y1KRL                     5&#8242; -TTTTTTTTCCATAGATTGGCGTTGCTGGGTCGTTTCTTTGA-3&#8242;                                           phoY1 knockout <br />    Y1KRR                     5&#8242; -TTTTTTTTCCATCTTTTGGCACGGATATCACGTTGGGGTAC-3&#8242;                                           phoY1 knockout <br />    Y2KLL                     5&#8242; -TTTTTTTTCCATAAATTGGCCCGCGTACCTCCGACATGAAG-3&#8242;                                           phoY2 knockout <br />    Y2KLR                     5&#8242; -TTTTTTTTCCATTTCTTGGTGGCGCTCACAATGGCTCTGAG-3&#8242;                                           phoY2 knockout <br />    Y2KRL                     5&#8242; -TTTTTTTTCCATAGATTGGGCCGATTCTACGAGCGCTTTGC-3&#8242;                                           phoY2 knockout <br />    Y2KRR                     5&#8242; -TTTTTTTTCCATCTTTTGGGCTGGCTGGCACGGATAACTGA-3&#8242;                                           phoY2 knockout <br />    Y1S                       5&#8242; -CGACCCCGTTGACGCACGCCGA-3&#8242;                                                              junction PCR <br />    Y1A                       5&#8242; -AGCGGTGTGCTGAAGTCGTGGG-3&#8242;                                                              junction PCR <br />    Y2S                       5&#8242; -ACGGACACCTTGTTCAACCTCA-3&#8242;                                                              junction PCR <br />    Y2A                       5&#8242; -CGTGCGAACCTACCAGAGCCT-3&#8242;                                                               junction PCR <br />    SacA                      5&#8242; -TGGTGGACCTCGACGACCCTAGA-3&#8242;                                                             junction PCR <br />    HygS                      5&#8242; -TTCGAGGTGTTCGAGGAGACCCC-3&#8242;                                                             junction PCR <br />    Y1CS                      5&#8242; -CGCGGAATTCCAGCCTGTTGAGCCCGATAA-3&#8242;                                                      phoY1 complementation <br />    Y1CA                      5&#8242; -CGCGAAGCTTCGATACAGGTGCACAACCGAA-3&#8242;                                                     phoY1 complementation <br />    Y2CS                      5&#8242; -CGCGGAATTCGCACCAGCAGGTTACGACGA-3&#8242;                                                      phoY2 complementation <br />    Y2CA                      5&#8242; -CGCGAAGCTTCTTCTCCAACCCGAACCAGA-3&#8242;                                                      phoY2 complementation <br />  <br />  <br /> antibiotic cocktail PANTA (Becton Dickinson, Sparks, MDk, USA) prevent    wild-type phoY1 phoY2 knockout mutants, <br /> contamination. Plates incubated 378C 5% CO2 environment         indicating successful construction DphoY1 DphoY2 <br /> for 4 weeks cfu counts determined. The Johns Hopkins Uni-        mutants M. tuberculosis. <br /> versity Animal Care Use Committee approved animal procedures. <br />  <br />  <br /> Statistical treatment                                                        Inactivation M. tuberculosis PhoU homologue PhoY2 <br /> Pairwise comparison cfu <span id='am-122' about='obo:NCBITaxon_1369087' typeof='obo:NCBITaxon_37567 owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_85604 obo:NCBITaxon_104431 obo:NCBITaxon_33154 obo:NCBITaxon_37570 obo:NCBITaxon_41191 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_33208 obo:NCBITaxon_41196 obo:NCBITaxon_197562 obo:NCBITaxon_85512 obo:NCBITaxon_197563 obo:NCBITaxon_95182 obo:NCBITaxon_41197 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_7088 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_7100 obo:NCBITaxon_33392 obo:NCBITaxon_50557'><span id='am-123'  ></span><span id='am-124' property="rdfs:label" content="Data" datatype="xsd:string"></span><span id='am-125' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-126' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>data</span> statistical significance         PhoY1 caused increased susceptibility <br /> performed using Student&#8217;s t-test.                                            TB drugs <br />                                                                              Since E. coli phoU mutant defect persister formation <br /> Results discussion                                                       demonstrated increased susceptibility antibiotics a <br />                                                                              reduced number persisters,16 subjected phoY1 and <br /> Construction DphoY1 DphoY2 mutants <br />                                                                              phoY2 mutants antibiotic susceptibility tests persister <br /> of M. tuberculosis H37Rv                                                     assays described Materials methods section. Inter- <br /> To determine effect mutation phoY1 phoY2                estingly, inactivation phoY2 caused increased susceptibility to <br /> persistence phenotype M. tuberculosis, constructed               TB drugs rifampicin pyrazinamide compared wild- <br /> knockout mutant DphoY1::hyg DphoY2::hyg alleles using                    type H37Rv MIC MBC experiments (see Table 2). <br /> specialized transduction temperature-sensitive phage                Specifically, MICs rifampicin pyrazinamide the <br /> phAE159 described Materials methods section.                   phoY2 mutant decreased 4-fold 2-fold, respectively, 7H9 <br /> Hygromycin-resistant colonies obtained, sug-                 liquid medium. The MBC rifampicin phoY2 mutant <br /> gestive double-crossover gene replacement event. Junction               4-fold parent strain H37Rv the <br /> PCR used confirm mutant genotype mutant                   MBC pyrazinamide remained unchanged (Table 2). However, <br /> alleles wild-type strain H37Rv control. The 666 bp             inactivation phoY1 did significantly alter susceptibility to <br /> (phoY1) 642 bp (phoY2) fragments observed                    rifampicin pyrazinamide MIC MBC experiments. <br />  <br />  <br />                                                                                                                                              1239 <br />  Shi Zhang <br />  <br />  <br />  <br /> Decreased persisters PhoY2 mutant PhoY1                          comparison defect persisters phoY2 <br /> mutant pyrazinamide rifampicin exposure                            mutant possible (data shown). In drug-free <br />                                                                             control, significant decrease cfu values the <br /> To determine effect pyrazinamide rifampicin the <br />                                                                             phoY2 phoY1 mutants control strain H37Rv, indicating <br /> persister survival phoY1 phoY2 mutants, subjected <br />                                                                             loss persisters rifampicin pyrazinamide <br /> stationary phase cultures parent strain H37Rv the <br />                                                                             exposure phoY2 mutant specific defect in <br /> above mutants pyrazinamide (200 mg/L) pH 5.6 rifam- <br />                                                                             phoY2 non-specific cell death the <br /> picin (8 mg/L) pH 7.0, determined cfu values 0, 3, 9 <br />                                                                             nutrient-limiting conditions exposure drug. These <br /> and 17 days exposure. No significant difference survival <br />                                                                             results suggest PhoY2, PhoY1, equivalent of <br /> between phoY1 phoY2 mutants parent strain <br />                                                                             E. coli PhoU M. tuberculosis. It note the <br /> H37Rv observed 3 days exposure pyrazina- <br />                                                                             defect persister survival phoY2 obvious the <br /> mide rifampicin (P.0.05). After 9 days pyrazinamide rifam- <br />                                                                             earlier timepoint 3 day drug exposure seen only <br /> picin exposure, difference survival between <br />                                                                             extended exposure 9 days. This consistent with <br /> phoY1 mutant parent strain H37Rv, survival of <br />                                                                             previous findings E. coli phoU mutant, which, the <br /> the phoY2 mutant greatly decreased persisters <br />                                                                             drug exposure persister assay, require relatively long <br /> were detectable (detection limit 100 bacteria) (Table 3). <br />                                                                             time persistence defect demonstrated.16 Future <br /> However, day 17, viable bacteria killed pyrazina- <br />                                                                             studies needed determine PhoY2 mutant <br /> mide mutants parent control strain H37Rv <br />                                                                             defective persistence TB drugs fluoro- <br />                                                                             quinolones aminoglycosides. <br />  <br /> Table 2. MIC MBC values (mg/L) phoY1 phoY2 mutants <br /> compared parent strain H37Rv                                           PhoY2 mutant defect persistence mouse <br />                                                                             model TB infection <br />                                          Strain <br />                                                                             To verify persister-defective phenotype the <br />                  H37Rv            phoY1 mutant           phoY2 mutant <br />                                                                             M. tuberculosis phoY2 mutant shown above, evaluated <br />                                                                             persistence phoY2 phoY1 mutants their <br /> Drug          MIC     MBC         MIC             MBC    MIC       MBC      respective complemented strains parent control <br />                                                                             strain H37Rv using low dose latent TB infection mouse model <br /> PZA pH 5.9   200     400      200             400       100       400       described Materials methods section. Mice were <br /> RIF            0.1     0.2      0.05 &#8211;0.1       0.2       0.025     0.05    infected comparably low numbers mycobac- <br />                                                                             terial strains ( 104 <span id='am-43' about='obo:NCBITaxon_91061' typeof='owl:Thing obo:NCBITaxon_1239 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_2'><span id='am-44' property="rdfs:label" content="Bacilli" datatype="xsd:string"></span><span id='am-45' property="oboInOwl:hasRelatedSynonym" content="Firmibacteria" datatype="xsd:string"></span><span id='am-46' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-47'  ></span><span id='am-48' property="oboInOwl:hasDbXref" content="PMID:20212322" datatype="xsd:string"></span><span id='am-49' property="oboInOwl:hasRelatedSynonym" content="Bacillus/Lactobacillus/Streptococcus group" datatype="xsd:string"></span><span id='am-50' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>bacilli</span>) described Materials and <br /> PZA, pyrazinamide; RIF, rifampicin.                                         methods section. The survival various mycobacterial strains <br /> The starting inocula used H37Rv, phoY1 phoY2 mutants were:          determined 8 weeks infection. As seen in <br /> 5&#215;105, 6.3&#215;105 6.3&#215;105, respectively. MIC/MBC testing per-          Table 4, PhoY2 mutant able survive persist <br /> formed 7H9 liquid medium described Materials               mouse lungs spleens shown  10- to <br /> methods section.                                                            30-fold decrease cfu counts compared virulent <br />  <br /> Table 3. PhoY2 mutant PhoY1 mutant reduced persisters vitro <br />  <br />                                                                                               Bacterial count (cfu/mL) <br />  <br /> Drug concentration                       Strain                          start                        day 3                         day 9 <br />  <br /> Pyrazinamide (pH 5.6, 7H9 ADC) <br />   200 mg/L                        H37Rv                            3.1+0.10&#215;106                   3.1+0.45&#215;105                  5.3+0.15&#215;103 <br />   200 mg/L                        H37Rv DphoY1                     3.2+0.17&#215;106                   4.3+0.50&#215;105                  3.3+0.15&#215;103 <br />   200 mg/L                        H37Rv DphoY2                     2.4+0.79&#215;106                  4.83+0.06&#215;105                    0a <br />   0 mg/L                          H37Rv                            3.1+0.10&#215;106                   6.9+0.46&#215;105                 1.33+0.15&#215;105 <br />   0 mg/L                          H37Rv DphoY1                     3.2+0.17&#215;106                  2.07+0.47&#215;106                 3.97+0.25&#215;105 <br />   0 mg/L                          H37Rv DphoY2                     2.4+0.79&#215;106                  4.77+1.05&#215;105                 2.77+0.15&#215;105 <br />  <br /> Rifampicin (pH 7.0, 7H9 ADC) <br />    200 mg/L                        H37Rv                           3.1+0.10&#215;108                  3.37+0.51&#215;105                 1.67+0.25&#215;104 <br />    200 mg/L                        H37Rv DphoY1                    3.2+0.17&#215;108                  4.97+0.70&#215;105                 3.13+0.31&#215;104 <br />    200 mg/L                        H37Rv DphoY2                    2.4+0.79&#215;108                  2.27+0.57&#215;105                    0a <br />    0 mg/L                          H37Rv                           3.1+0.10&#215;108                  1.33+0.40&#215;109                  3.5+0.26&#215;108 <br />    0 mg/L                          H37Rv DphoY1                    3.2+0.17&#215;108                   2.0+0.35&#215;109                 3.57+0.32&#215;108 <br />    0 mg/L                          H37Rv DphoY2                    2.4+0.79&#215;108                  1.37+0.32&#215;109                  3.0+0.40&#215;108 <br />  <br /> a <br /> Below detection limit 100 bacteria. <br />  <br />  <br />  <br /> 1240 <br />  PhoU homologue PhoY2 involved TB persistence                                                                                     JAC <br />                 Table 4. Survival phoY1 phoY2 mutants complemented strains mice <br />  <br />                                                           Beginning cfu                 cfu/spleen                  cfu/lung <br />  <br />                 H37Rv                                    0.84+0.11&#215;104              3.03+0.19&#215;103               1.20+0.10&#215;102 <br />                 H37Rv DphoY1                             1.18+0.09&#215;104              7.39+0.48&#215;103               3.73+0.27&#215;102 <br />                 H37Rv DphoY1 complemented                1.25+0.35&#215;104              4.38+0.85&#215;103               3.81+0.92&#215;102 <br />                 H37Rv DphoY2                             1.13+0.27&#215;104              1.71+1.16&#215;102*               1.6+1.0&#215;101* <br />                 H37Rv DphoY2 complemented                1.35+0.40&#215;104              5.82+0.62&#215;103               4.89+0.40&#215;102 <br />  <br />                 The phoY2 mutant 10- 30-fold fewer cfu lungs spleen control parent strain H37Rv <br />                 (*P,0.05 compared cfu control H37Rv). Complementation phoY2 mutant restored level <br />                 persistence parent strain H37Rv. There significant difference survival persistence <br />                 lungs spleen H37Rv, phoY1 mutant complemented strains (P. 0.05). <br />  <br />  <br />  <br /> parent strain H37Rv (P,0.05), PhoY1 mutant sur-               phenotype TB drugs aminoglycosides qui- <br /> vived persisted H37Rv control strain. Interest-        nolones, long-term persistence phoY2 mutant the <br /> ingly, complementation PhoY2 mutant wild-type             mouse model elucidate mechanism which <br /> phoY2 gene restored persistence phenotype PhoY2                phoY2 mediates persistence M. tuberculosis. <br /> mutant wild-type level H37Rv spleens                    In conclusion, shown M. tuberculosis PhoU <br /> lungs (Table 4). This experiment validates PhoY2                 homologue PhoY2 PhoY1 equivalent E. coli <br /> mutant vitro defect persister survival           PhoU demonstrated increased susceptibility TB drugs <br /> drug exposure assays shown above, exhibited                defect persistence mouse model. This is <br /> in vivo persistence defect mouse model (Table 4).                  study confirms role PhoU persistence in <br />     Our data suggest PhoY2 mutation does alter persistence           different organism (i.e. M. tuberculosis) E. coli. Studies <br /> as shown persister drug exposure assay, mouse study            currently underway address detailed mechanisms of <br /> and MIC/MBC values PhoY2 mutant. There sig-           PhoU PhoY2 mediates persister formation. The identifi- <br /> nificant debate regarding persister mutants              cation PhoY2 involved mycobacterial persistence <br /> alteration MIC/MBC values. It proposed persister         significant finding implications under- <br /> mutants alter MIC affect persistence.24           standing mechanism persistence development <br /> However, necessarily true mutation persis-          new drugs vaccines target persister organisms for <br /> ter genes affect antibiotic susceptibility         improved control TB. <br /> persisters shown persister assays growing bac- <br /> teria shown MIC/MBC tests case PhoU mutation16 <br /> and SucB UbiF mutations.25 In addition, found <br /> that mutants defect persistence have <br />                                                                           Acknowledgements <br /> altered MIC/MBC values (J. Chen Y. Zhang, unpublished data).          We grateful Bill Jacobs providing mycobacterial plasmids and <br />                                                                           phages. <br />     It demonstrated PhoU expression correlated <br /> with persister formation expressed stationary <br /> phase aged cultures nutrient-limiting conditions16,26 <br /> or overexpressed biofilms E. coli.27 In PhoU overexpres-        Funding <br /> sion study using arabinose-inducible pBAD vector,           This work supported NIH grant AI44063. <br /> overexpression phoU caused increased persister formation in <br /> log phase E. coli cultures, overexpression control genes <br /> ruvA, fur rcsB involved L-form formation28 same <br /> vector did (W. Shi Y. Zhang, unpublished observation).            Transparency declarations <br /> Studies underway assess controlled overexpres-             None declare. <br /> sion phoY2 leads increased persister formation in <br /> M. tuberculosis. More recently, consistent previous <br /> finding PhoU important persister formation                 References <br /> E. coli,16 Lee et al. 29 PhoU played critical role        1 WHO. World Health Organization Tuberculosis (TB). http://www.who.int/ <br /> persister phenotype <span id='am-51' about='obo:NCBITaxon_303' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_1224 obo:NCBITaxon_2 obo:NCBITaxon_286 obo:NCBITaxon_1236 obo:NCBITaxon_72274 obo:NCBITaxon_135621 obo:NCBITaxon_136845'><span id='am-52' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-53' property="oboInOwl:hasRelatedSynonym" content="Bacillus putidus" datatype="xsd:string"></span><span id='am-54' property="oboInOwl:hasRelatedSynonym" content="Pseudomonas eisenbergii" datatype="xsd:string"></span><span id='am-55' property="oboInOwl:hasAlternativeId" content="NCBITaxon:105847" datatype="xsd:string"></span><span id='am-56' property="oboInOwl:hasRelatedSynonym" content="Pseudomonas ovalis" datatype="xsd:string"></span><span id='am-57' property="oboInOwl:hasRelatedSynonym" content="Pseudomonas incognita" datatype="xsd:string"></span><span id='am-58' property="oboInOwl:hasDbXref" content="PMID:17978216" datatype="xsd:string"></span><span id='am-59' property="oboInOwl:hasRelatedSynonym" content="Arthrobacter siderocapsulatus" datatype="xsd:string"></span><span id='am-60' property="oboInOwl:hasAlternativeId" content="NCBITaxon:760256" datatype="xsd:string"></span><span id='am-61' property="oboInOwl:hasRelatedSynonym" content="Bacillus fluorescens putidus" datatype="xsd:string"></span><span id='am-62' property="oboInOwl:hasRelatedSynonym" content="Pseudomonas arvilla" datatype="xsd:string"></span><span id='am-63' property="oboInOwl:hasAlternativeId" content="NCBITaxon:1416793" datatype="xsd:string"></span><span id='am-64' property="oboInOwl:hasAlternativeId" content="NCBITaxon:931954" datatype="xsd:string"></span><span id='am-65' property="oboInOwl:hasRelatedSynonym" content="Pseudomonas sp. PX-A-Ps.sp2" datatype="xsd:string"></span><span id='am-66' property="oboInOwl:hasRelatedSynonym" content="Pseudomonas convexa" datatype="xsd:string"></span><span id='am-67' property="oboInOwl:hasRelatedSynonym" content="Pseudomanas putida" datatype="xsd:string"></span><span id='am-68' property="oboInOwl:hasRelatedSynonym" content="Pseudomonas rugosa" datatype="xsd:string"></span><span id='am-69' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-70' property="oboInOwl:hasAlternativeId" content="NCBITaxon:126995" datatype="xsd:string"></span><span id='am-71' property="oboInOwl:hasDbXref" content="PMID:11211254" datatype="xsd:string"></span><span id='am-72' property="oboInOwl:hasDbXref" content="PMID:1177780" datatype="xsd:string"></span><span id='am-73'  ></span><span id='am-74' property="oboInOwl:hasDbXref" content="PMID:9734035" datatype="xsd:string"></span><span id='am-75' property="oboInOwl:hasAlternativeId" content="NCBITaxon:931964" datatype="xsd:string"></span><span id='am-76' property="oboInOwl:hasAlternativeId" content="NCBITaxon:29437" datatype="xsd:string"></span><span id='am-77' property="rdfs:label" content="Pseudomonas putida" datatype="xsd:string"></span><span id='am-78' property="oboInOwl:hasRelatedSynonym" content="Pseudomonas striata" datatype="xsd:string"></span><span id='am-79' property="oboInOwl:hasAlternativeId" content="NCBITaxon:668614" datatype="xsd:string"></span><span id='am-80' property="oboInOwl:hasAlternativeId" content="NCBITaxon:79218" datatype="xsd:string"></span><span id='am-81' property="oboInOwl:hasAlternativeId" content="NCBITaxon:691260" datatype="xsd:string"></span>Pseudomonas putida</span> shown higher              tb/en/ (9 October 2009, date accessed). <br /> susceptibility decreased persisters phoU mutant. It            2 CDC. Emergence Mycobacterium tuberculosis extensive <br /> is note phoY2 (Rv0821c) significantly             resistance second-line drugs - worldwide, 2000-2004. MMWR Morb <br /> up-regulated 96 h nutrient starvation persistence model           Mortal Wkly Rep 2006; 55: 301&#8211;5. <br /> M. tuberculosis,30 suggesting phoY2 important             3 Gandhi NR, Moll A, Sturm AW et al. Extensively drug-resistant <br /> mycobacterial persistence. Our findings study provide             tuberculosis cause death patients co-infected with <br /> further evidence phoY2 involved persistence M. <span id='am-127' about='obo:NCBITaxon_36048' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_4751 obo:NCBITaxon_40289 obo:NCBITaxon_33154 obo:NCBITaxon_451864 obo:NCBITaxon_147538 obo:NCBITaxon_5185 obo:NCBITaxon_4890 obo:NCBITaxon_716545 obo:NCBITaxon_2759 obo:NCBITaxon_147549'><span id='am-128' property="rdfs:label" content="Tuber" datatype="xsd:string"></span><span id='am-129' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-130' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-131'  ></span><span id='am-132' property="oboInOwl:hasExactSynonym" content="truffles" datatype="xsd:string"></span>tuber</span>-       tuberculosis HIV rural area South Africa. Lancet 2006; 368: <br /> culosis. Future studies needed determine persister             1575&#8211; 80. <br />  <br />  <br />  <br />                                                                                                                                            1241 <br />  Shi Zhang <br />  <br />  <br />  <br /> 4 WHO. XDR-TB, Extensively Drug-Resistant Tuberculosis. http://www.who.       19 Dahl JL, Kraus CN, Boshoff HI et al. The role RelMtb-mediated <br /> int/tb/challenges/xdr/en/index.html (21 September 2009, date             adaptation stationary phase long-term persistence of <br /> accessed).                                                                    Mycobacterium tuberculosis mice. Proc Natl Acad Sci USA 2003; 100: <br /> 5 McDermott W. Microbial persistence. Yale J Biol Med 1958; 30: 257&#8211;91.       10026&#8211;31. <br /> 6 Zhang Y. The magic bullets tuberculosis drug targets. Annu Rev          20 Bardarov S, Kriakov J, Carriere C et al. Conditionally replicating <br /> Pharmacol Toxicol 2005; 45: 529&#8211; 64.                                          mycobacteriophages: transposon delivery to <br />                                                                               Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1997; 94: 10961&#8211; 6. <br /> 7 Mitchison D. The search new sterilizing anti-tuberculosis drugs. <br /> Front Biosci 2004; 9: 1059&#8211; 72.                                               21 Zhang Y, Garbe T, Young D. Transformation katG restores <br />                                                                               isoniazid-sensitivity Mycobacterium tuberculosis isolates resistant a <br /> 8 Hobby GL, Meyer K, Chaffee E. Observations mechanism of <br />                                                                               range drug concentrations. Mol Microbiol 1993; 8: 521&#8211;4. <br /> action penicillin. Proc Soc Exp Biol NY 1942; 50: 281&#8211; 5. <br />                                                                               22 Wade MM, Zhang Y. Effects weak acids, UV proton motive force <br /> 9 Bigger JW. Treatment staphylococcal infections penicillin. <br />                                                                               inhibitors pyrazinamide activity Mycobacterium tuberculosis <br /> Lancet 1944; 244: 497&#8211; 500. <br />                                                                               vitro. J Antimicrob Chemother 2006; 58: 936&#8211; 41. <br /> 10 Balaban NQ, Merrin J, Chait R et al. Bacterial persistence a <br />                                                                               23 Orm <br /> </body></html>